Circulating irisin levels reflect visceral adiposity in non-diabetic patients undergoing hemodialysis

Basit Öğe Kaydı
dc.authoridBilgic, Mukadder Ayse/0000-0003-0621-8273|Darcin, Tahir/0000-0001-5073-1790;
dc.contributor.authorYilmaz, Hakki
dc.contributor.authorCakmak, Muzaffer
dc.contributor.authorDarcin, Tahir
dc.contributor.authorInan, Osman
dc.contributor.authorSahiner, Enes
dc.contributor.authorDemir, Canan
dc.contributor.authorAktas, Aynur
dc.date.accessioned2025-10-24T18:09:44Z
dc.date.available2025-10-24T18:09:44Z
dc.date.issued2016
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBackground: Recent evidence suggests that increased visceral adiposity is a strong independent risk factor for cardiovascular death and all-cause mortality in hemodialysis (HD) patients. Irisin, which is a novel myokine, can play critical roles in diabetes and adiposity. The purpose of our study was to investigate whether serum irisin levels are associated with body mass index, waist circumference (WC), and total fat mass in non-diabetic patients undergoing maintenance HD.Methods: This cross-sectional study included 108 non-diabetic HD patients and 40 age- and sex-matched apparently healthy subjects. Serum irisin concentrations were determined using an enzyme-linked immunosorbent assay. Body fat composition (TBF-410 Tanita Body Composition Analyzer) was measured and calculated.Results: Serum irisin levels did not differ between HD patients and the healthy controls (523.50 +/- 229.32 vs. 511.28 +/- 259.74, p=0.782). Serum irisin levels were associated with age (r=0.314; p=0.006), HOMA-IR (r=0.472; p=0.003), WC (r=0.862; p<0.001), and total fat mass (r=0.614; p<0.001). In multivariate regression analysis, WC (=1.240, p<0.001) and total fat mass (=0.792, p=0.015) were the variables that were significantly associated with irisin concentrations (R-2=0.684, p<0.001) after adjusting for confounding factors (age and HOMA-IR). Conclusions: These results suggest that serum irisin levels are related to visceral adiposity in non-diabetic HD patients.
dc.identifier.doi10.3109/0886022X.2016.1172918
dc.identifier.endpage919
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.issue6
dc.identifier.pmid27089215
dc.identifier.scopus2-s2.0-84963864353
dc.identifier.scopusqualityQ2
dc.identifier.startpage914
dc.identifier.urihttps://doi.org/10.3109/0886022X.2016.1172918
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3791
dc.identifier.volume38
dc.identifier.wosWOS:000379778100009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofRenal Failure
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectAbdominal obesity; adiposity; hemodialysis; irisin
dc.titleCirculating irisin levels reflect visceral adiposity in non-diabetic patients undergoing hemodialysis
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu